文献速递肝病消化道肿瘤与早癌

恩替卡韦或替诺福韦治疗慢性乙型肝炎超过10年后的肝细胞癌风险仍持续存在:PAGE-B队列结果

Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results from the PAGE-B cohort.
PubMed 文献 · J Hepatol · 2026-07-06

PAGE-B长期队列纳入1,644例接受恩替卡韦或替诺福韦治疗的慢性乙型肝炎白种人患者,其中903例随访超过10年(平均14±2年)。10年和15年肝细胞癌累积发生率分别为10.9%和13.2%;肝细胞癌发生率在10年前为1.25/100人年,10年后降至0.55/100人年(p<0.001)。尽管发生率下降,肝细胞癌仍是死亡率的主要决定因素,HBsAg清除率在10年后升高但仍较低。

要点

  • 恩替卡韦或替诺福韦治疗超过10年,肝细胞癌风险仍持续存在,需继续长期监测。
  • 肝细胞癌发生率10年后显著下降(1.25 vs 0.55/100人年,p<0.001),但仍是长期结局的主要决定因素。
  • HBsAg清除率10年和15年累积分别为8.3%和14.3%,10年后发生率升高但仍较低。

核心结论

  • 尽管接受恩替卡韦或替诺福韦治疗超过10年,慢性乙型肝炎患者仍存在肝细胞癌风险,但发生率显著下降。
  • 肝细胞癌仍是死亡率的主要决定因素,需要持续长期监测和风险分层。
  • HBsAg清除率在10年后逐渐升高但仍较低,功能学治愈不常见。

研究设计与样本

  • PAGE-B长期队列研究,纳入1,644例接受恩替卡韦或替诺福韦治疗的慢性乙型肝炎白种人患者。
  • 其中903例随访超过10年,平均随访14±2年。
  • 采用Kaplan-Meier法或竞争风险累积发生率函数估计累积发生率,计算每100人年发生率。

主要发现

  • 10年和15年肝细胞癌累积发生率分别为10.9%和13.2%。
  • 肝细胞癌发生率在10年前为1.25/100人年,10年后为0.55/100人年(p<0.001),逆概率加权后结果相似。
  • 死亡或肝移植发生率在10年前后分别为1.50 vs 1.95/100人年(p=0.069),肝脏相关死亡/肝移植发生率分别为0.74 vs 0.70/100人年(p=0.840)。
  • 10年和15年HBsAg清除累积发生率分别为8.3%和14.3%;HBsAg清除发生率从10年前的0.94/100人年升至10年后的1.42/100人年(p=0.025)。
  • 125例(7.6%)HBsAg阳性患者停用核苷(酸)类似物治疗。

关键数值与推荐

  • 肝细胞癌发生和基线血小板计数与无肝移植的肝脏相关或总体生存独立相关,后者还与高龄和糖尿病相关。
  • HBsAg清除与高龄和基线HBeAg阳性独立相关。

临床怎么用

  • 对接受恩替卡韦或替诺福韦治疗超过10年的慢性乙型肝炎患者,应继续长期监测肝细胞癌。
  • 应持续进行风险分层,尤其关注基线血小板计数较低或合并其他危险因素的患者。
  • 延长抗病毒治疗可能带来持续获益,但功能学治愈仍不常见,需合理管理患者预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Long-term outcome data in patients with chronic hepatitis B (CHB) treated with high-genetic-barrier nucleos(t)ide analogues (NAs) beyond year 10 are scarce. We assessed the incidence and predictors of hepatocellular carcinoma (HCC), liver transplantation (LT), all-cause and liver-related death, and HBsAg loss among patients treated with NAs for >10 years. METHODS: The long-term PAGE-B cohort included 1,644 Caucasian patients with CHB treated with entecavir or tenofovir. Cumulative incidence was estimated using Kaplan-Meier methods or cumulative incidence functions accounting for competing events. Incidence rates (IRs) per 100 person-years (/100 PYs) were calculated. RESULTS: Of 1,644 patients, 903 were followed beyond year 10 (mean:14 ± 2 years). The 10- and 15-year cumulative incidences of HCC were 10.9% and 13.2%, respectively. The HCC IR was 1.25 before year 10 and 0.55/100 PYs after year 10 (p <0.001), with similar findings after inverse probability weighting. The IR of death or LT was lower before vs. after year 10 (1.50 vs. 1.95/100 PYs, p = 0.069), whereas the IR was similar for liver-related death/LT between the two periods (0.74 vs. 0.70/100 PYs, p = 0.840). HCC development and baseline platelet count were independently associated with LT-free liver-related or overall survival, which was also associated with older age and diabetes. The 10- and 15-year cumulative incidences of HBsAg loss on NA(s) were 8.3% and 14.3%, respectively; the IR of HBsAg loss increased from 0.94 before year 10 to 1.42/100 PYs after year 10 (p = 0.025). HBsAg loss was independently associated with older age and baseline HBeAg positivity. NA therapy was discontinued in 125 (7.6%) patients who remained HBsAg positive. CONCLUSIONS: Despite >10 years of NA therapy, patients with CHB remain at risk of HCC, although the incidence rate declines significantly. HCC remains the main determinant of mortality. The rate of HBsAg loss increases after year 10 but remains low, occurring more frequently in older patients and those who were initially HBeAg positive. IMPACT AND IMPLICATIONS: Despite more than 10 years of effective nucleos(t)ide analogue therapy, patients with chronic hepatitis B remain at risk of hepatocellular carcinoma, highlighting the need for continued long-term surveillance. Although the incidence of hepatocellular carcinoma declined after year 10, it remained the main determinant of long-term outcomes. These findings reinforce the importance of sustained risk stratification, particularly among patients with lower baseline platelet counts or other risk factors. The gradual increase in hepatitis B surface antigen loss beyond 10 years provides further evidence that prolonged antiviral therapy may offer ongoing benefits, although functional cure remains uncommon and is more likely among older patients and those who were initially HBeAg-positive.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Papatheodoridis GV, Dalekos G, Idilman R, et al. Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results from the PAGE-B cohort. J Hepatol. 2026. PMID: 42409322. doi:10.1016/j.jhep.2026.06.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。